Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear

03 Feb 2017

• By Mandy Jackson

Related Content

‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales

06 Jan 2017

Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition

28 Oct 2016

Amgen's Repatha Emerges Unscathed In GLAGOV PCSK9 Imaging Study

16 Nov 2016

PCSK9 Patent Fight: Amgen Opposes Doctor Efforts To Keep Praluent On Market

27 Jan 2017

The Next PCSK-9 Pricing Debate: PBM Says Outcomes Data Should Mean Deeper Discount

09 Dec 2016

Related Companies

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Additional Topics

Commercial Business Strategies Clinical Trials Reimbursement Cardiovascular BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.